
Oncology NEWS International
- Oncology NEWS International Vol 15 No 6
- Volume 15
- Issue 6
Phase I Trial of an Oral/Oral Combination Accruing Patients
GPC Biotech AC is accruing patients with advanced solid tumors onto a phase I trial of satraplatin, its investigational oral platinum agent, in combination with capecitabine (Xeloda). The open label study of the oral/oral combination, led by William Gradishar, MD, of Northwestern University, is expected to enroll approximately 24 patients, the company indicated in a news release.
MARTINSREID/MUNICH, GermanyGPC Biotech AC is accruing patients with advanced solid tumors onto a phase I trial of satraplatin, its investigational oral platinum agent, in combination with capecitabine (Xeloda). The open label study of the oral/oral combination, led by William Gradishar, MD, of Northwestern University, is expected to enroll approximately 24 patients, the company indicated in a news release.
Articles in this issue
almost 20 years ago
Triple-Negative Cancers More Common in Young Black Ptsalmost 20 years ago
Artists Turn Flowers & Curves Into 'Forms' and 'Figures'almost 20 years ago
Study to Examine Outcomes Disparities in Pediatric ALLalmost 20 years ago
Thalidomide Has 'Changed the Paradigm' in Myeloma Rxalmost 20 years ago
CA4P Gets Orphan Drug Statusalmost 20 years ago
Testicular Ca Survivors at Increased Risk for CV Eventsalmost 20 years ago
A Novel Brings a Cancer Research Laboratory to Lifealmost 20 years ago
NCCN Reveals New Venous Thromboembolism Guidelinealmost 20 years ago
Lapatinib New Option for Metastatic HER2+ Breast Caalmost 20 years ago
FDA Approves Dacogen for Treating All MDS SubtypesNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.























































